US02043Q1076 - Common Stock - After market: 219.64 0 (0%)
/PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), empresa líder em terapias de RNAi, acaba de anunciar que a Agência Nacional de Vigilância...
Alnylam Pharmaceuticals Inc. said it’s stopping work on a treatment for a rare eye disease because of a new US drug-pricing law with the potential to limit how much it could charge for the medication in the future.
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Bear market, shmear market. These biotech stocks are soaring despite the market downturn.